AZ firms up immuno-oncology imaging deal with ImaginAbAstraZeneca has expanded its alliance with ImaginAb, an imaging specialist developing imaging agents to increase the efficacy and Share XAZ firms up immuno-oncology imaging deal with ImaginAbhttps://pharmaphorum.com/news/az-firms-up-immuno-oncology-imaging-deal-with-imaginab/
Merck, Pfizer’s Bavencio flunks head and neck cancer trialMerck KGaA and Pfizer’s checkpoint inhibitor Bavencio has failed a phase 3 trial in head and neck cancer, Share XMerck, Pfizer’s Bavencio flunks head and neck cancer trialhttps://pharmaphorum.com/news/merck-pfizers-bavencio-flunks-head-and-neck-cancer-trial/
Roche hops on Bicycle’s drug discovery platform for cancerRoche’s recent spate of billion-dollar plus alliances has continued with a deal with UK biotech Bicycle Therapeutics – Share XRoche hops on Bicycle’s drug discovery platform for cancerhttps://pharmaphorum.com/news/roche-hops-on-bicycles-drug-discovery-platform-for-cancer/
ALX Oncology cancer drug claims two FDA fast-track reviewsFresh from a $105 million third-round financing earlier this month, ALX Oncology has won two FDA fast-track designations Share XALX Oncology cancer drug claims two FDA fast-track reviewshttps://pharmaphorum.com/news/alx-oncology-cancer-drug-claims-two-fda-fast-track-reviews/
Gilead closes in on second CAR-T approval in USThe FDA is due to decide by 10 August whether it will approve a second CAR-T therapy from Share XGilead closes in on second CAR-T approval in UShttps://pharmaphorum.com/news/gilead-closes-in-on-second-car-t-approval-in-us/
EMA starts review of second CAR-T from Gilead’s Kite unitThe EU regulator has started its review of a second CAR-T from Gilead Sciences’ Kite Pharma subsidiary, setting Share XEMA starts review of second CAR-T from Gilead’s Kite unithttps://pharmaphorum.com/news/ema-starts-review-of-second-car-t-from-gileads-kite-unit/
Roche files Tecentriq, Avastin combo as a liver cancer therapyRoche has filed for approval of a two-drug combination of its Tecentriq and Avastin drugs in previously-untreated hepatocellular Share XRoche files Tecentriq, Avastin combo as a liver cancer therapyhttps://pharmaphorum.com/news/roche-files-tecentriq-avastin-combo-as-a-liver-cancer-therapy/
China’s Adagene raises $69m for cancer immunotherapiesChinese biotech Adagene has raised $69 million in fourth-round financing to help usher its immuno-oncology drugs – including Share XChina’s Adagene raises $69m for cancer immunotherapieshttps://pharmaphorum.com/news/chinas-adagene-raises-69m-for-cancer-immunotherapies/
Roche steps up Merck challenge with first-line NSCLC approval in USRoche has scored another FDA approval for Tecentriq alongside chemotherapy for previously-untreated, non-squamous non-small cell lung cancer (NSCLC), Share XRoche steps up Merck challenge with first-line NSCLC approval in UShttps://pharmaphorum.com/news/roche-continues-merck-challenge-with-first-line-nsclc-approval-in-us/
